STOCK TITAN

Longeveron Inc - LGVN STOCK NEWS

Welcome to our dedicated news page for Longeveron (Ticker: LGVN), a resource for investors and traders seeking the latest updates and insights on Longeveron.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Longeveron's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Longeveron's position in the market.

Rhea-AI Summary
Longeveron Inc. announced that the Phase 2 ELPIS II trial for the treatment of HLHS has surpassed the 50% enrollment threshold. An additional study location has been activated to expedite enrollment completion. A webinar will be held to discuss the potential of Lomecel-B™ in improving outcomes for HLHS patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
-
Rhea-AI Summary
Longeveron Inc. (LGVN) to Report Second Quarter 2023 Financial Results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
conferences earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.13%
Tags
management
-
Rhea-AI Summary
Longeveron Inc. announces that Chairman, Co-founder, and Chief Science Officer Joshua Hare has been inducted as a fellow of the National Academy of Inventors for his research on stem cell therapies for heart disease. Dr. Hare's induction took place on June 27, 2023. Longeveron's lead therapeutic candidate is Lomecel-B™, a potential alternative therapy for damaged hearts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
none
Rhea-AI Summary
Longeveron Inc. announces the election of three new directors, Wa’el Hashad, Khoso Baluch, and Jeffrey Pfeffer, at the Annual Meeting of Stockholders. The new directors bring significant experience in biotechnology and corporate management. Wa’el Hashad will also serve as the new Chief Executive Officer. Longeveron is excited about the potential of its lead investigational product, Lomecel-B™, and looks forward to accelerated progress in its clinical programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.35%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.58%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
Longeveron Inc

Nasdaq:LGVN

LGVN Rankings

LGVN Stock Data

5.37M
1.13M
6.71%
14.27%
1.12%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Miami

About LGVN

longeveron llc is a leading global regenerative medicine company developing innovative cellular therapeutics for chronic life-threatening diseases. our lead investigational product candidate (lmsc) is based on a specialized cell known as a mesenchymal stem cell that is derived from the bone marrow of healthy young adult donors. our allogeneic, ‘off-the-shelf’ product is under investigation for chronic conditions of the elderly, and other life- threatening diseases, for which no approved therapeutics currently exist: • aging frailty syndrome • alzheimer’s disease • hypoplastic left heart syndrome • the metabolic syndrome